Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Catabasis Pharma (CATB)

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,867
  • Shares Outstanding, K 11,797
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,870 K
  • 60-Month Beta 1.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.62
  • Number of Estimates 2
  • High Estimate -0.56
  • Low Estimate -0.67
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +27.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.61 +7.81%
on 10/23/19
5.64 -11.88%
on 11/04/19
+0.24 (+5.07%)
since 10/22/19
3-Month
4.42 +12.44%
on 10/07/19
6.89 -27.87%
on 08/27/19
-1.74 (-25.93%)
since 08/22/19
52-Week
3.60 +38.06%
on 12/27/18
9.76 -49.08%
on 04/11/19
-0.91 (-15.48%)
since 11/21/18

Most Recent Stories

More News
Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress

-- Conference Call and Webcast Today at 8:30am ET --

CATB : 4.99 (-0.40%)
Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2019 financial results before the Nasdaq Global Market open on Thursday, November 7,...

CATB : 4.99 (-0.40%)
Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys...

CATB : 4.99 (-0.40%)
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented the findings from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label...

CATB : 4.99 (-0.40%)
Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular...

CATB : 4.99 (-0.40%)
Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by...

CATB : 4.99 (-0.40%)
Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and the Jain Foundation, a non-profit foundation whose mission is to cure muscular dystrophies caused by dysferlin...

CATB : 4.99 (-0.40%)
Catabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial Officer

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Andrew A. Komjathy as Chief Commercial Officer. Mr. Komjathy brings to Catabasis...

CATB : 4.99 (-0.40%)
Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress

-- Recent Data Supports Potential for Bone Preservation with Edasalonexent in DMD --

CATB : 4.99 (-0.40%)
Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Hugh M. Cole to its Board of Directors. Mr. Cole has more than 20 years of...

JNCE : 4.70 (-1.67%)
CATB : 4.99 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

The current trending strength of the market is Average.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CATB with:

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 5.23
1st Resistance Point 5.11
Last Price 4.99
1st Support Level 4.85
2nd Support Level 4.71

See More

52-Week High 9.76
Fibonacci 61.8% 7.41
Fibonacci 50% 6.68
Fibonacci 38.2% 5.95
Last Price 4.99
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar